BRIEF-AstraZeneca Says Kestrel Phase III Trial For Imfinzi Did Not Meet Primary Endpoint

Reuters · 02/05/2021 07:10
BRIEF-AstraZeneca Says Kestrel Phase III Trial For Imfinzi Did Not Meet Primary Endpoint

- AstraZeneca PLC AZN.L:

  • ASTRAZENECA PLC - UPDATE ON KESTREL PHASE III TRIAL FOR IMFINZI

  • ASTRAZENECA - KESTREL PHASE III TRIAL FOR ASTRAZENECA'S IMFINZI (DURVALUMAB) DID NOT MEET PRIMARY ENDPOINT OF IMPROVING OVERALL SURVIVAL

  • ASTRAZENECA - SAFETY AND TOLERABILITY PROFILES FOR IMFINZI AS A MONOTHERAPY AND IN COMBINATION WITH TREMELIMUMAB WERE CONSISTENT WITH PREVIOUS TRIALS

  • ASTRAZENECA - COMBINATION OF IMFINZI PLUS TREMELIMUMAB DID NOT INDICATE AN OS BENEFIT IN 'ALL-COMER' PATIENTS, A SECONDARY ENDPOINT.

Source text for Eikon: ID:nRSE1314Oa

Further company coverage: AZN.L


((Reuters.Briefs@thomsonreuters.com;))